Literature DB >> 15332228

Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation.

Frank Firkin1, Prudence A Hill, Karen Dwyer, Hilton Gock.   

Abstract

Specific treatment of light-chain deposition disease has been reported as ineffective in altering the course of the severe or end-stage renal failure it causes. The authors describe a case of biopsy-proven primary light-chain deposition disease of the kidney, severe renal failure, and incipient dialysis dependency, treated by autologous peripheral blood stem cell transplantation, that led to reversal of dialysis dependency and sustained improvement in renal function.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15332228

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


  8 in total

1.  Systemic and rapidly progressive light-chain deposition disease initially presenting as tubulointerstitial nephritis.

Authors:  Satoko Takahashi; Jun Soma; Izaya Nakaya; Mayumi Yahata; Tsutomu Sakuma; Hiroshi Yaegashi; Akiyoshi Sato; Masaharu Wano; Hiroshi Sato
Journal:  CEN Case Rep       Date:  2012-07-19

2.  Durable hematological response and improvement of nephrotic syndrome on thalidomide therapy in a patient with refractory light chain deposition disease.

Authors:  Haruyuki Fujita; Masakatsu Hishizawa; Soichiro Sakamoto; Tadakazu Kondo; Norimistu Kadowaki; Takayuki Ishikawa; Junji Itoh; Atsushi Fukatsu; Takashi Uchiyama; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2011-04-09       Impact factor: 2.490

3.  Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case report.

Authors:  Abdul Moiz; Tariq Javed; Jorge Garces; Catherine Staffeld-Coit; Paisit Paueksakon
Journal:  Ochsner J       Date:  2014

4.  Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma.

Authors:  Ala Abudayyeh; Heather Lin; Omar Mamlouk; Maen Abdelrahim; Rima Saliba; Gabriela Rondon; Charles S Martinez; Ruby Delgado; Valda Page; Arun Rajasekaran; Paul W Sanders; Muzaffar Qazilbash
Journal:  Leuk Lymphoma       Date:  2020-07-29

5.  Long-term reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous stem cell transplantation.

Authors:  Tomás J González-López; Lourdes Vázquez; Teresa Flores; Jesus Fernando San Miguel; Ramon García-Sanz
Journal:  Clin Pract       Date:  2011-11-23

6.  Long-term renal survival of γ3-heavy chain deposition disease: a case report.

Authors:  Takayuki Katsuno; Shige Mizuno; Masatsuna Mabuchi; Naotake Tsuboi; Atsushi Komatsuda; Shoichi Maruyama
Journal:  BMC Nephrol       Date:  2017-07-17       Impact factor: 2.388

7.  [Clinical features and prognosis of patients with primary light chain deposition disease].

Authors:  J N Wang; J Feng; X X Cao; M H Duan; L Zhang; D B Zhou; J Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-03-14

Review 8.  The pathogenesis of renal injury and treatment in light chain deposition disease.

Authors:  Qi Wang; Fang Jiang; Gaosi Xu
Journal:  J Transl Med       Date:  2019-11-25       Impact factor: 5.531
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.